How effective is Entresto?
The PARADIGM-HF trial compared the efficacy of Entresto 200 mg (97/103 mg) twice daily versus enalapril 10 mg twice daily in 8,442 patients with NYHA Class II-IV heart failure and systolic dysfunction. Patients were already taking the maximum tolerated dose of a beta blocker and an angiotensin converting enzyme inhibitor (ACEi) or ARB. The median follow-up duration was 27 months and patients were treated for up to 4.3 years. At the conclusion of the study, 21.8% of patients in the Entresto group had a cardiovascular (CV) event or were hospitalized compared to 26.5% of patients who received enalapril. The Entresto treatment group also had a lower rate of death from cardiovascular causes when compared to the enalapril treatment group (13.3% versus 16.5%). Entresto was superior to enalapril in reducing the risk of cardiovascular death, hospitalizations due to heart failure, and all-cause mortality.
Interesting Facts about Entresto
Entresto is the first drug in a new class of medications known as angiotensin-receptor neprilysin inhibitors (ARNIs)
Sacubitril is a prodrug.
The PARADIGM-HF clinical trial was ended early because Entresto was very effective.
Entresto was shown to be better than enalapril, an ACEi, which is a gold standard treatment for patients with heart failure and low ejection fraction.
Next: Side Effects, Dosage, Drug Interactions